7L5O
Crystal structure of the noncovalently bonded complex of rilzabrutinib with BTK
Summary for 7L5O
Entry DOI | 10.2210/pdb7l5o/pdb |
Descriptor | Tyrosine-protein kinase BTK, (2E)-2-{(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl}-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile, DIMETHYL SULFOXIDE, ... (8 entities in total) |
Functional Keywords | protein kinase inhibitor, transferase-transferase inhibitor complex, transferase, transferase/transferase inhibitor |
Biological source | Homo sapiens (Human) |
Total number of polymer chains | 1 |
Total formula weight | 32727.54 |
Authors | Bradshaw, J.M.,Brameld, K.A.,Mrosek, M.,Lammens, A.,Blaesse, M. (deposition date: 2020-12-22, release date: 2022-06-29, Last modification date: 2024-04-03) |
Primary citation | Owens, T.D. The Discovery Rilzabrutinib (PRN1008): A Reversible Covalent BTK Inhibitor for Immune Mediated Diseases To Be Published, |
Experimental method | X-RAY DIFFRACTION (1.21 Å) |
Structure validation
Download full validation report![Download](/newweb/media/icons/dl.png)
![Download](/newweb/media/icons/dl.png)